Navigation Links
3SBio Announces Conversion of Isotechnika Debenture
Date:11/18/2010

SHENYANG, China, Nov. 18, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2.58 million of a US$4.5 million debenture convertible into Isotechnika Pharma Inc. ("Isotechnika") common shares issued on August 23, 2010. As a result, Isotechnika issued an additional 17,516,000 common shares at C$0.155 per common share to 3SBio. The common shares are subject to a four month plus one day hold which commenced on August 23, 2010.  Prior to this conversion, 3SBio owned 13,000,000 common shares of Isotechnika. The US$4.5 million debenture has now been fully converted and 3SBio owns approximately 18.83% of the issued and outstanding shares of Isotechnika.

The debenture was acquired in conjunction with the strategic partnership with Isotechnika to develop and commercialize voclosporin in China announced on August 24, 2010. 3SBio will continually review its investment alternatives and may purchase or sell securities of Isotechnika from time to time in accordance with applicable securities laws.

3SBio has also filed a report with the Canadian regulatory authorities containing additional information (the "Early Warning Report").  A copy of the Early Warning Report will appear with Isotechnika's documents on the SEDAR website, at www.sedar.com and may also be obtained by contacting the persons listed below.  

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX".  3SBio's address is No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang, China 110027. Please see www.3SBio.com for more information. Investor Contacts  Bo TanChief Financial Officer3SBio Inc.Tel: + 86 24 2581-1820 ir@3SBio.comTom FolinsbeeDirector of Investor Relations3SBio Inc. Tel: + 852 8191-6991ir@3SBio.com
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
2. 3SBio Announces Partial Conversion of Isotechnika Debenture
3. 3SBio Announces Investor Conference Schedule
4. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
5. 3SBio Inc. Announces Results of Annual General Meeting
6. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
7. Medivir Announces Positive 24-week Interim Data of TMC435 From the ASPIRE Study (C206)
8. GSI Group Inc. Announces John Roush to Become Chief Executive Officer
9. Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014
10. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
11. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and ... primary and secondary endpoint data for lasmiditan, an investigational, ... which demonstrated statistically significant improvements compared to placebo in ... highlighted today at the 18th Congress of the International ... "The data presented today demonstrate lasmiditan,s potential ...
Breaking Medicine Technology:
(Date:9/22/2017)... , ... September 22, 2017 , ... Happy Living’s mission ... time - carries it into the entertaining and delicious worlds of theatre and ... (founder of Happy Living) convinced him to turn his play into a book. The ...
(Date:9/22/2017)... ... 22, 2017 , ... TopConsumerReviews.com recently awarded their highest five-star ... promote pancreatic health and regulate blood sugar levels . , Preventing diabetes ... negative side effects, and with the changes in today’s healthcare industry, not everyone ...
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released ... doorstep. According to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, ... customers can find clothing at discounted prices. Apart from this, Smart Mart has ...
(Date:9/21/2017)... Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... been so fun and easy to do. Users can select from up to two ... all with a click of a mouse all within Final Cut Pro X. ...
Breaking Medicine News(10 mins):